Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Eikon Therapeutics presented initial and updated Phase 1/2 data for its three clinical programs — PARP1-selective inhibitors EIK1003 and EIK1004 and WRN helicase inhibitor EIK1005 — at the 2026 ESMO Congress in Madrid. EIK1003 showed manageable safety and preliminary antitumor activity in monotherapy and combination cohorts, with ORRs of 14.3% in HRR-mutant monotherapy, 20.8% with abiraterone in prostate cancer, and 26.4% with weekly paclitaxel in ovarian/breast cancer. CNS-penetrant EIK1004 demonstrated minimal hematologic toxicity with no dose-limiting toxicities across 68 dosed participants, and WRN inhibitor EIK1005 was well tolerated with a PK profile supporting weekly dosing.
Key figures
- Drug Name
- EIK1003, EIK1004, EIK1005
- Phase Of Trial
- Phase 1/2
- Eik1004 orr
- 12.1% (7/58); DCR 62.1%
- Eik1003 cohort 1a orr
- 14.3% (7/49); 31.3% in PARP-naive
- Eik1003 cohort 1b orr
- 20.8% (5/24); DCR 83.3%
- Eik1003 cohort 1c orr
- 26.4% (14/53); DCR 79.2%
- Eik1005 half life days
- 9.4
- Eik1005 participants dosed
- 11
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.